Related articles

• γ-catenin alleviates cardiac fibrosis through inhibiting phosphorylation of GSK-3β
  2020, 34(1): 27-35. DOI: 10.7555/JBR.33.20190070
• Hepatic ischemia-reperfusion injury in liver transplant setting: mechanisms and protective strategies
  2019, 33(4): 221-234. DOI: 10.7555/JBR.32.20180087
• Preparation, optimization, and characterization of chitosancoated solid lipid nanoparticles for ocular drug delivery
  2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
• Non-alcoholic fatty liver disease: a narrative review of genetics
  2018, 32(6): 389-400. DOI: 10.7555/JBR.32.20180045
• Non-alcoholic fatty liver disease–a chronic disease of the 21st century
  2018, 32(5): 327-335. DOI: 10.7555/JBR.31.20160153
• Acute-on-chronic liver failure: recent update
  2017, 31(4): 283-300. DOI: 10.7555/JBR.30.20160060
• Protein inhibitor of activated STAT 4 (PIAS4) regulates liver fibrosis through modulating SMAD3 activity
  2016, 30(6): 496-501. DOI: 10.7555/JBR.30.20160049
• Impact of IL28B gene polymorphisms rs8099917 and rs12980275 on response to pegylated interferon-a/ribavirin therapy in chronic hepatitis C genotype 4 patients
  2016, 30(1): 40-45. DOI: 10.7555/JBR.30.20150002
• Lipoprotein metabolism in nonalcoholic fatty liver disease
  2013, 27(1): 1-13. DOI: 10.7555/JBR.27.20120077
• The efficacy of NP11-4-derived immunotoxin scFv-artesunate in reducing hepatic fibrosis induced by Schistosoma japonicum in mice
  2011, 25(2): 148-154. DOI: 10.1016/S1674-8301(11)60019-5